P/B
21,8
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
$10.2B
Market Cap • 9/22/2026
1989
(37 years)
Founded
1995
(31 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
15,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,3
EPS
—
Market Cap
Market Cap
10,2B
EV
10B
EV/Revenue
14,9
EV/EBITDA
-49,6
EV/EBIT
-44
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-3,1%
Total Yield
-3,1%
Payout
0%
Retained Earnings
-1,9B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
108%
Capex/Revenue
2,4%
Capex/D&A
62,2%
Capex/OCF
-27,2%
SBC/OCF
—
% PPE
20,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
44,1%
CAGR Op. Income 5Y
11%
CAGR Net Income 5Y
16,7%
CAGR EPS 5Y
12,8%
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
5,9
Quick Ratio
5,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!